**Supplementary Table 2.** **Correlation between TMCO3 expression and clinicopathological factors in the local validated cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** | **Subcategory** | **PCR cohort, *n*=52** | **IHC cohort, *n*=105** |
| **Count** | **Low** | **High** | ***p*** | **Count** | **Low** | **High-moderate** | ***p*** |
| Sex | Female | 4 | 2 | 2 | 0.695 | 14 | 1 | 13 | 0.260 |
|  | Male | 48 | 24 | 24 |  | 91 | 17 | 74 |  |
| Age, years | ≤50 | 28 | 13 | 15 | 0.578 | 61 | 9 | 52 | 0.444 |
|  | >50 | 24 | 13 | 11 |  | 44 | 9 | 35 |  |
| HBsAg | Negative | 12 | 9 | 3 | 0.048 | 15 | 2 | 13 | 0.503 |
|  | Positive | 40 | 17 | 23 |  | 90 | 16 | 74 |  |
| Cirrhosis  | Absence | 18 | 12 | 6 | 0.080 | 39 | 6 | 33 | 0.713 |
|  | Present | 34 | 14 | 20 |  | 66 | 12 | 54 |  |
| AFP, ng/ml | ≤200 | 32 | 18 | 14 | 0.254 | 70 | 12 | 58 | 1.000 |
|  | >200 | 20 | 8 | 12 |  | 35 | 6 | 29 |  |
| Tumor size | ≤5 | 26 | 12 | 14 | 0.579 | 47 | 4 | 43 | 0.035 |
| (cm) | >5 | 26 | 14 | 12 |  | 58 | 14 | 44 |  |
| Tumor number | Single | 32 | 17 | 15 | 0.569 | 74 | 14 | 60 | 0.456 |
|  | multiple | 20 | 9 | 11 |  | 31 | 4 | 27 |  |
| Pathological differentiation | High-medium | 6 | 4 | 2 | 0.334 | 7 | 2 | 5 | 0.344 |
|  | Low | 46 | 22 | 24 |  | 98 | 16 | 82 |  |
| BCLC stage | 0-A | 11 | 3 | 8 | 0.090 | 48 | 8 | 40 | 0.905 |
|  | B-C | 41 | 23 | 18 |  | 57 | 10 | 47 |  |

AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBsAg, hepatitis B surface antigen.